Novel Therapeutic Options in Patients with Type 2 Diabetes and high cardiovascular Risk

被引：0
|
作者：
Laubner, Katharina [1 ]
Seufert, Jochen [2 ]
机构：
[1] Univ Freiburg Klinikum, Klin Innere Med 2, Abt Endokrinol & Diabetol, Freiburg, Germany
[2] Univ Freiburg Klinikum, Klin Innere Med 2, Endokrinol & Diabetol, Freiburg, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2016年 / 141卷 / 11期
关键词：
MELLITUS;
D O I：
10.1055/s-0042-107747
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SGLT2 inhibitors represent a novel therapeutic approach for the tretment of type 2 diabetes mellitus. Beyond glucose control, these drugs also induce weight loss and blod pressure reduction. In a specific cardiovascular outcome trial (EMPA-REG-OUTCOME), the SGLT 2 inhibitor empagliflozin has for the first time demonstrated to reduce cardiovascular and overall mortality as well as hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. These results will drastically affect future recommendations for the treatment of type 2 diabetes mellitus.). © Georg Thieme Verlag KG ·Stuttgart · New York.
引用
收藏
页码：757 / 760
页数：4
相关论文
共 50 条
  • [41] Assumption of therapeutic responsibility of cardiovascular risk in type 2 diabetes - Entred study
    Marant, C
    Fosse, S
    Romon, I
    Weill, A
    Simon, D
    Varroud-Vial, M
    Malinsky, M
    Fagot-Campagna, A
    DIABETES & METABOLISM, 2006, 32 : S87 - S87
  • [42] Cardiovascular risk management in type-2 diabetes: Is the patients' cardiovascular risk adequately considered in type-2 specialist diabetes care?
    Brenner, Sophie
    Daikeler, Richard
    Oberaigner, Willi
    Stummer, Harald
    ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2021, 167 : 6 - 14
  • [43] Cardiovascular risk in type 2 diabetes
    Standl, E
    DIABETES OBESITY & METABOLISM, 1999, 1 : S24 - S36
  • [44] Type 2 diabetes and cardiovascular risk
    Robinson, Jennifer G.
    Schmeltz, Lowell R.
    Stone, Neil J.
    MEDICAL CLINICS OF NORTH AMERICA, 2008, 92 : 37 - 48
  • [45] Risk of cardiovascular disease very high in patients with type 1 diabetes
    Nature Clinical Practice Cardiovascular Medicine, 2006, 3 (8): : 407 - 408
  • [46] High fitness is associated with a better cardiovascular risk profile in patients with type 2 diabetes mellitus
    Claudia RL Cardoso
    Maicon DL Maia
    Fátima P de Oliveira
    Nathalie C Leite
    Gil F Salles
    Hypertension Research, 2011, 34 : 856 - 861
  • [47] Cardiovascular prevention in high-risk patients with type 2 diabetes mellitus:: when to start it?
    Mellbin, Linda G.
    Ryden, Lars
    Malmberg, Klas
    Norhammar, Anna
    Wedel, Hans
    EUROPEAN HEART JOURNAL, 2008, 29 (16) : 2058 - 2059
  • [48] Plasma Leptin in Patients at Intermediate to High Cardiovascular Risk With and Without Type 2 Diabetes Mellitus
    Montagnana, Martina
    Fava, Cristiano
    Targher, Giovanni
    Franchini, Massimo
    Danese, Elisa
    Bonafini, Sara
    De Cata, Angela
    Salvagno, Gian Luca
    Ruzzenente, Orazio
    Guidi, Gian Cesare
    Lippi, Giuseppe
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2017, 31 (02)
  • [49] EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK
    Fitchett, David H.
    Inzucchi, Silvio
    Lachin, John
    Wanner, Christoph
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans-Juergen
    Broedl, Uli C.
    Zinman, Bernard
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1869 - 1869
  • [50] High fitness is associated with a better cardiovascular risk profile in patients with type 2 diabetes mellitus
    Cardoso, Claudia R. L.
    Maia, Maicon D. L.
    de Oliveira, Fatima P.
    Leite, Nathalie C.
    Salles, Gil F.
    HYPERTENSION RESEARCH, 2011, 34 (07) : 856 - 861
12345